X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.fiercebiotech.com/biotech/syndax-and-incyte-both-reeling-from-cancer-drug-setbacks-pen-chronic-graft-versus-host
https://investors.kadmon.com/news-releases/news-release-details/kadmon-announces-us-availability-rezurocktm-belumosudil
https://investors.kadmon.com/news-releases/news-release-details/kadmon-announces-rezurocktm-belumosudil-added-national
https://www.biospace.com/article/kadmon-wins-first-fda-approval-for-chronic-gvhd-drug-/
https://www.chemdiv.com/kadmon-shares-jump-on-fda-approval-of-rezurock-for-chronic-gvhd/#:~:text=Shares%20in%20Kadmon%20Pharmaceuticals%20were,prior%20lines%20of%20systemic%20therapy.
https://investors.kadmon.com/news-releases/news-release-details/kadmon-announces-us-fda-has-extended-review-period-belumosudil
https://www.biospace.com/article/releases/kadmon-announces-12-month-data-from-pivotal-trial-of-belumosudil-for-cgvhd-at-the-62nd-ash-annual-meeting/
https://investors.kadmon.com/news-releases/news-release-details/kadmon-present-12-month-data-pivotal-trial-belumosudil-cgvhd
https://seekingalpha.com/news/3618595-kadmon-files-us-application-for-belumosudil-in-gvhd
https://markets.businessinsider.com/news/stocks/kadmon-announces-submission-of-new-drug-application-to-the-u-s-fda-for-belumosudil-in-patients-with-chronic-graft-versus-host-disease-1029637786
Market Place
Share 
